Sandbox:Mitra3
Therapuetic Considerations in RVMI | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reperfusion | Maintenance of RV preload | Decreased RV afterload | Restoring Rate/Rhythm and AV synchrony | Inotropic support | Mechanical Circulatory Support | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
•Thrmobolytics •Percutaneous coronary intervention (PCI) | • Avoidance of preload reducing agents, such as:
| • Systemic or pulmonary vasodilators: | • In patients with bradyarrhthmias: | • In patients with refractory hypotension: | May be needed in patients with cardiogenic shock secondary to RVMI | {{{ }}} | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||